IGHE and Alzheimer disease: Several studies have shown the ineffectiveness of omalizumab as a therapeutic agent in AD [24,25], suggesting that increased IgE levels could be an epiphenomenon of AD, mediating comorbidities such as food allergies, asthma, and rhinoconjunctivitis, but not the AD itself [20].